Correlation of in vitro activity and in vivo efficacy of itraconazole intravenous and oral solubilized formulations by testing Candida strains with various itraconazole susceptibilities in a murine invasive infection

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 626-634

  Uchida, Katsuhisa ^a   Shimogawara, Kosuke ^b   Yamaguchi, Hideyo ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Candida infected mice; In vitro antifungal activity; In vivo efficacy; Intravenous formulation; Itraconazole; Oral solution

Indexed keywords

ITRACONAZOLE; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SURVIVAL; ANIMAL; CANDIDIASIS; DISEASE MODEL; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; ORAL DRUG ADMINISTRATION; RODENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; RODENT DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79951541787     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq475     Document Type: Article

References (45)

1. Van Cutsem J. The in-vitro antifungal spectrum of itraconazole. Mycoses 1989; 32 Suppl 1: 7-13.
2. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann Pharmacother 1992; 26: 502-9.
3. Denning DW, Tucker RM, Hansen LH et al. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791-800.
4. Smith D, Van De Velde V, Woestenborghs R et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharmacol 1992; 44: 618-9.
5. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal azoles. Antimicrob Agents Chemother 1992; 36: 477-80.
6. Barone JA, Maskovitz BL, Guarnieri J et al. Enhanced bioavailability of itraconazole in hydroxypropyl-b-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-5.
7. Prentice HG, Caillot D, Dupont B et al. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: meeting reports. Acta Haematol 1999; 101: 56-62.
8. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28: 250-5.
9. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
10. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
11. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-9.
12. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-9.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.
15. Espinel-Ingroff A, Barchiesi F, Hazen KC et al. Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol 1998; 36 Suppl 1: 68-78.
16. He X, Tiballi RN, Zarins LT et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 2495-7.
17. Guennec RL, Reynes J, Mallie M et al. Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 1995; 33: 3732-7.
18. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
19. Cartledge JD, Midgley J, Petrou M et al. Unresponsive HIV-related oro-oesophageal candidosis-an evaluation of two new in-vitro azole susceptibility tests. J Antimicrob Chemother 1997; 40: 517-23.
20. Revankar SG, Kirkpatrick WR, McAtee RK et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998; 36: 153-6.
21. Yamaguchi H, Uchida K, Okuzumi K et al. Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan from the Japan Antifungal Surveillance Program (JASP), 2001-2002. J Jpn Soc Clin Microbiol 2004; 14: 183-93.
22. Yamaguchi H, Nishiyama Y, Uchida K et al. Nationwide survey of antifungal drug susceptibility of clinical fungal isolated in Japan from the Japan Antifungal Surveillance Program (JASP), 2005. J Jpn Soc Clin Microbiol 2009; 19: 128-41.
23. Peto R, Pike MC, Armitage NE et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
24. DeBeule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61 Suppl 1: 27-37.
25. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29: S37-41.
26. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 Suppl 1: 103-8.
27. Bradford CR, Prentice AG, Warnock DW et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukemia. J Antimicrob Chemother 1991; 28: 555-60.
28. Glasmacher A, Hahn C, Molitor E et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-b-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
29. Prentice AG, Donnelly P. Oral antifungals as prophylaxis in haematological malignancy. Blood Rev 2001; 15: 1-8.
30. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26: 15-69.
31. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 Suppl S1: i17-22.
32. Tei M, Yamamoto M, Inoue K et al. Single- and multiple-dose pharmacokinetics of itraconazole oral solution in healthy men. Jpn J Chemother 2006; 54 Suppl 1: 6-17.
33. Boogaerts MA, Maertens J, van der Geest R et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001; 45: 981-5.
34. Kohno S, Yamaguchi H, Mori T et al. Efficacy and safety of itraconazole injections and capsules in deep mycosis. Jpn J Chemother 2006; 54 Suppl 1: 32-47.
35. Lee D-G, Chae H, Yim D-S et al. Population pharmacokinetics of intravenous itraconazole in patients with persistent neutropenic fever. J Clin Pharm Ther 2009; 34: 337-44.
36. Shin JH, Choi KY, Kim YC et al. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 2004; 48: 1756-62.
37. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 1994; 28 Suppl 1: 17-24.
38. Anaissie EJ, Karyotakis NC, Hachem H et al. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170: 384-9.
39. Caillot D, Bassaris H, McGeer A et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83-90.
40. Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109: 111-8.
41. Patterson TF, Fothergill AW, Rinaldi MG. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 1993; 37: 2307-10.
42. Miyazaki HM, Kohno S, Miyazaki Y et al. Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1993; 37: 2762-5.
43. Tansho S, Abe S, Ishibashi H et al. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice. J Infect Chemother 2006; 12: 355-62.
44. Rex JH, Nelson PW, Paetznick VL et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129-34.
45. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000; 44: 2081-5.